Analysts at UBS said they are watching multiple catalysts in their SMID oncology coverage heading into a busy fourth quarter ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE